IP Library Granted Patent US 12,061,198
Granted Patent B2
US 12,061,198 · App. 16/601,627 · Granted Aug 13, 2024

Diagnosis and treatment of viral diseases

Inventors: Gerard Nuovo (Westerville, OH); Virginia Nivar (Marion, OH)
Assignee: ENZO BIOCHEM, INC
G01N33/56994C07K16/085C07K16/244C12Q1/6883C12Q1/6886C12Q1/701C12Q1/705C07K2317/33C07K2317/76C12N2710/16021C12Q2600/118C12Q2600/158G01N2333/03G01N2800/7052
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,061,198
App. No.
16/601,627
Granted
Aug 13, 2024
Kind
B2
Abstract

Provided are methods of diagnosing a viral disease such as idiopathic pulmonary fibrosis, Castleman's disease, a lymphoma, a thymoma or a sarcoma in a patient by identifying one or more virus-specific elements such as a nucleic acid or a viral protein or a patient antibody to a virus-specific element, as well as to kits for diagnosing the viral disease in a patient. Further provided are methods of monitoring disease progression and/or the efficacy of therapy by measuring the levels of a virus-specific element in a sample from a patient, and methods of identifying therapeutic agents that show efficacy in reducing levels of virus-specific agents in vitro. Still further provided are methods of treating idiopathic pulmonary fibrosis, a lymphoproliferative disease and cancer, as well as to methods of preventing viral infection, including Herpesvirus saimiri infection.

Claims (7)

1. A composition comprising a viral nucleic acid target sequence hybridized to

a non-radioactively labeled nucleic acid comprising one or more nucleic acid sequences complementary to Herpesvirus saimiri , wherein the non-radioactive label comprises a fluorescent label, a chemiluminescent label, a hapten label, a chromogenic label, or an energy transfer pair element, wherein the non-radioactively labeled nucleic acid is completely complementary to a sequence of at least 20 contiguous nucleotides within ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14

and wherein the composition is present in a human cell in an isolated lung tissue specimen.

2. The composition of claim 1 , wherein the viral nucleic acid target sequence has the nucleotide sequence of Herpesvirus saimiri.

3. The composition of claim 1 , wherein the non-radioactively labeled nucleic acid is labeled with biotin.

4. The composition of claim 1 , wherein the non-radioactively labeled nucleic acid comprises at least one locked nucleic acid (LNA) oligonucleotide.

5. The composition of claim 1 , wherein the non-radioactively labeled nucleic acid comprises a nucleotide sequence of SEQ ID:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: NUOVO, GERARD; NIVAR, VIRGINIA
To: ENZO BIOCHEM, INC.
Reel/Frame 050837/0765 →
Continuity (7)
Continuation 15897217 · Feb 15, 2018
Continuation 15439495 · Feb 22, 2017
Continuation 14759687
Continuation In Part 14080644 · Nov 14, 2013
Continuation In Part 13920964 · Jun 18, 2013
Provisional Application 61750104 · Jan 8, 2013
Related Publication 20200110088A1 · Apr 9, 2020